It is one of the more uncomfortable facts in modern psychiatry: people with schizophrenia die 10 to 20 years earlier than the general population, and the largest single cause is not suicide — it is cardiovascular disease. The World Health Organization notes that this premature mortality is largely preventable. The gap has not narrowed meaningfully in decades, despite better antipsychotics and better community care, largely because the cardiovascular side of the equation has been chronically under-treated.
Most people with schizophrenia who die early are not dying from psychosis. They are dying from heart attacks, strokes, and sudden cardiac death — most of which are preventable with the same interventions used in the general population, if they're actually delivered.
The size of the problem
A landmark 2015 study in JAMA Psychiatry by Olfson and colleagues found that the standardised mortality ratio for cardiovascular disease in schizophrenia was roughly 3.6 — meaning death rates are several times higher than in age-matched peers. Subsequent meta-analyses have found similar patterns across many countries. The mortality gap is widest for cardiovascular causes and has not closed even as overall life expectancy in the general population has increased.
Why the cardiovascular risk is higher
The classic risk factors are stacked
- Smoking — roughly 60% of people with schizophrenia smoke, often heavily
- Diabetes and prediabetes — see our diabetes article
- Obesity and abdominal adiposity — driven partly by antipsychotics, partly by reduced activity
- Hypertension — under-detected and under-treated
- Dyslipidaemia — particularly high triglycerides, which several antipsychotics worsen
Antipsychotic-specific contributions
Beyond metabolic effects, some antipsychotics carry direct cardiovascular concerns:
- QT prolongation — a small but real arrhythmia risk, particularly with ziprasidone, iloperidone, and high-dose haloperidol. See our QT guide.
- Orthostatic hypotension — falls, fainting, and (rarely) cardiac strain
- Clozapine-related myocarditis and cardiomyopathy — rare but serious, particularly in the first 8 weeks
System-level barriers
People with schizophrenia receive fewer cardiovascular screenings, fewer statins when indicated, fewer cardiac procedures after a heart attack, and worse hypertension control than the general population — even when they have the same insurance coverage. This is what mental health researchers call "diagnostic overshadowing": physical complaints get attributed to psychiatric symptoms and dismissed.
What screening should look like
Adapted from the ADA/APA consensus and the European Psychiatric Association guidance:
- Baseline (before starting an antipsychotic): weight, waist, blood pressure, fasting glucose or HbA1c, fasting lipids, smoking status, family history
- Repeat at 3 months: weight, glucose, lipids
- At least annually: full metabolic and cardiovascular review
- 10-year cardiovascular risk score: every few years (e.g., the Framingham, ASCVD, or QRISK calculators)
Chest pain or pressure, sudden shortness of breath, fainting, severe palpitations, weakness or numbness on one side of the body, sudden trouble speaking, or sudden severe headache. Do not "wait it out."
What actually moves the needle
1. Smoking cessation
This is the single highest-yield intervention. Quitting smoking in schizophrenia is harder than in the general population (see our guide), but the cardiovascular benefit is enormous and begins within months.
2. Statins when indicated
Statins are dramatically under-prescribed in this population. If LDL cholesterol is elevated and risk score is moderate or high, the benefit-risk balance is generally strongly in favour. They are well tolerated and don't meaningfully interact with most antipsychotics.
3. Blood pressure control
Hypertension is also under-treated. ACE inhibitors and ARBs are first-line and generally well tolerated. Asking the prescriber to actually check the number, repeatedly, and treat to target makes a measurable difference.
4. Switching antipsychotics where possible
If metabolic markers are deteriorating on olanzapine or clozapine, switching to a metabolically lighter alternative can be considered — always weighing relapse risk. See our switching guide.
5. Cardio-respiratory fitness
Even modest improvements in fitness measurably reduce mortality. The exercise guide goes into the practicalities of building a routine when motivation is low.
6. Integrated care
Models where a primary care provider is embedded into the mental health clinic produce better cardiovascular outcomes than separate, parallel care. Ask about whether your clinic offers this.
Sudden cardiac death
People with schizophrenia have a roughly two- to three-fold increase in sudden cardiac death compared with the general population. Some of this is QT-related; much of it is the cumulative effect of cardiovascular risk factors. Avoiding combinations of QT-prolonging drugs, monitoring electrolytes (especially potassium and magnesium), and treating coronary risk factors all reduce this risk.
The takeaway
The mortality gap is not destiny. The interventions are not exotic — they are the same things any cardiologist would recommend for anyone else, delivered consistently, in a system that takes physical health in serious mental illness as seriously as it takes psychiatric stability. Patients and families who advocate for that level of care often do considerably better than those who don't.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.